These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9065544)

  • 21. Cardiovascular autonomic dysfunction in dementia with Lewy bodies and Parkinson's disease.
    Oka H; Morita M; Onouchi K; Yoshioka M; Mochio S; Inoue K
    J Neurol Sci; 2007 Mar; 254(1-2):72-7. PubMed ID: 17306830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
    Przuntek H; Conrad B; Dichgans J; Kraus PH; Krauseneck P; Pergande G; Rinne U; Schimrigk K; Schnitker J; Vogel HP
    Eur J Neurol; 1999 Mar; 6(2):141-50. PubMed ID: 10053226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. The Parkinson Study Group.
    Shoulson I
    Eur Neurol; 1992; 32 Suppl 1():46-53. PubMed ID: 1425820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity.
    van Dijk JG; Haan J; Zwinderman K; Kremer B; van Hilten BJ; Roos RA
    J Neurol Neurosurg Psychiatry; 1993 Oct; 56(10):1090-5. PubMed ID: 8410008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Takahashi M; Yuasa R; Imai T; Tachibana H; Yorifuji S; Nakamura Y; Ogawa N
    Intern Med; 1994 Sep; 33(9):517-24. PubMed ID: 8000101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of autonomic functions of patients with multiple system atrophy and Parkinson's disease by head-up tilt test.
    Watano C; Shiota Y; Onoda K; Sheikh AM; Mishima S; Nitta E; Yano S; Yamaguchi S; Nagai A
    J Neural Transm (Vienna); 2018 Feb; 125(2):153-162. PubMed ID: 29185078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selegiline: initial or adjunctive therapy of Parkinson's disease?
    Fuller MA; Tolbert SR
    DICP; 1991 Jan; 25(1):36-40. PubMed ID: 1901185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations.
    Oka H; Yoshioka M; Onouchi K; Morita M; Mochio S; Suzuki M; Hirai T; Urashima M; Inoue K
    Mov Disord; 2007 Jul; 22(10):1510-1514. PubMed ID: 17516497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relation between autonomic dysfunction and progression of Parkinson's disease].
    Oka H; Mochio S; Inoue K
    Rinsho Shinkeigaku; 2001 Jun; 41(6):283-8. PubMed ID: 11771156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study.
    Baschieri F; Sambati L; Guaraldi P; Barletta G; Cortelli P; Calandra-Buonaura G
    Parkinsonism Relat Disord; 2021 Dec; 93():12-18. PubMed ID: 34758441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyposmia and cardiovascular dysautonomia correlatively appear in early-stage Parkinson's disease.
    Mizutani Y; Nakamura T; Okada A; Suzuki J; Watanabe H; Hirayama M; Sobue G
    Parkinsonism Relat Disord; 2014 May; 20(5):520-4. PubMed ID: 24637128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease.
    Ludwig J; Remien P; Guballa C; Binder A; Binder S; Schattschneider J; Herzog J; Volkmann J; Deuschl G; Wasner G; Baron R
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):742-5. PubMed ID: 17371906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.